CHANGES TO HATCH-WAXMAN REFORMS BECOMING EVIDENT
Since new drug patent rules went into effect last year, the FDA has not received a single polymorph patent for filing in the Orange Book, according to agency officials, who are seeking input on implementing the changes to the Hatch-Waxman Act patent law.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.